Mumps Virus Vaccine, Live, Jeryl Lynn Strain
The Mumps Virus Vaccine Live, Jeryl Lynn Strain is a live attenuated vaccine that provides active immunization against mumps, a contagious viral infection affecting the salivary glands. The Jeryl Lynn strain, derived from the actual mumps virus isolated from Dr. Maurice Hilleman's daughter in the 1960s, is the strain used in the widely administered MMR (measles, mumps, rubella) combination vaccine. This vaccine is primarily given to children as part of routine childhood immunization schedules to prevent mumps and its potential complications, which can include meningitis, encephalitis, and orchitis.
A live attenuated vaccine using the Jeryl Lynn strain to prevent mumps infection, typically administered as part of routine childhood immunization.
Key facts at a glance
- RxNorm
- 798372
- Generic
- Mumps Virus Vaccine Live, Jeryl Lynn Strain
- Class
- unclassified
- Brands
- M-M-R II, Priorix, ProQuad
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of mumps caused by infection with the mumps virus. It is indicated for immunization of persons 12 months of age and older, typically administered as part of the MMR combination vaccine during childhood. May be given to older children, adolescents, and adults without evidence of immunity who are at risk of mumps exposure.
The vaccine contains live but weakened (attenuated) mumps virus of the Jeryl Lynn strain. After administration, the attenuated virus replicates in the body to stimulate the immune system to produce antibodies against the mumps virus without causing the disease itself. This acquired immunity provides protection against future wild-type mumps virus exposure.
This is a live vaccine and is contraindicated in immunocompromised individuals, pregnant women, and those with severe allergic reactions to vaccine components. Common side effects may include fever, rash, or mild swelling of salivary glands. Vaccine effectiveness is approximately 78-95% after two doses. Should not be given within 3 months of receiving blood products or immunoglobulin.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 29, 2026. · Read our editorial policy